Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Gross PP&E Adjustments (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other Gross PP&E Adjustments over the past 14 years, most recently at $186.4 million for Q2 2025.

  • For Q2 2025, Other Gross PP&E Adjustments fell 5.4% year-over-year to $186.4 million; the TTM value through May 2025 reached $186.4 million, down 5.4%, while the annual FY2025 figure was $186.4 million, 5.4% down from the prior year.
  • Other Gross PP&E Adjustments for Q2 2025 was $186.4 million at Lifecore Biomedical, Inc. \De\, up from $181.5 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $202.6 million in Q4 2024 and troughed at -$15.4 million in Q1 2021.
  • A 5-year average of $76.6 million and a median of -$3.3 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 50.11% in 2021 and later skyrocketed 7330.6% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at -$7.5 million in 2021, then rose by 29.87% to -$5.3 million in 2022, then rose by 23.14% to -$4.0 million in 2023, then skyrocketed by 5120.89% to $202.6 million in 2024, then fell by 8.01% to $186.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for LFCR at $186.4 million in Q2 2025, $181.5 million in Q1 2025, and $202.6 million in Q4 2024.